Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Infliximab in Polymyositis and Dermatomyositis

Study Design:

Phase 1-2, randomized, placebo controlled, cross-over trial. Infliximab dose 5-7.5 mg/kg, NIH only

Types & Number of IIM Studied:

Active Polymyositis and Dermatomyositis (N = 12)

Entry Criteria:

Probable or definite Bohan and Peter criteria for polymyositis or dermatomyositis, Refractory to methotrexate, azathioprine, or another immunosuppressive agent, as well as steroids

IMACS Core Set Measures Included:

All: Physician and Patient Global Activity Assessments, Manual Muscle Testing, enzymes, Health Assessment Questionnaire, Myositis Disease Activity Assessment Tool; Myositis Damage Index, Health-Related Quality of Life by SF-36

Other Measures Included:

Magnetic resonance imaging, flow cytometry, microarrays, cytokine levels/genes, MHC typing

Primary Outcome:

IMACS Definitions of Improvement and 15% increase of Manual Muscle Testing alone

Study Duration:

16 weeks treatment, placebo crossover to treatment for 16 weeks more with total duration 70 weeks

Funding:

NIAMS, NIH; Centocor

Comments:

Enrollment Completed

Publications:

Dastmalchi M1, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg I. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies., Ann Rheum Dis, 2008 Dec;67(12):1670-7. [Abstract Dastmalchi M1, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg I. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies., Ann Rheum Dis, 2008 Dec;67(12):1670-7.]

Contact:

Paul Plotz, M.D.
Tel 301-496-1474
plotzp@mail.nih.gov
Back
to Top